Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent [...]
Uppsala, Sweden, May 4 2017. Biovica has received an order for the company's product DiviTum® from a global contract research company (CRO company), commissioned by a global pharmaceutical company to study the effectiveness of new cancer drugs.
Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at [...]
Lund University includes DiviTum® in study for treatment efficacy evaluation of breast cancer patients
Lund University select Biovicas DiviTum® assay for inclusion in a study of 150 women with metastatic breast cancer. The purpose of the study is faster evaluation of treatment efficacy than current standard methods. Lund University will buy about 550 DiviTum tests.
Biovica will participate in a EUROSTAR research project called SUBLYME, that will develop a new targeted drug for blood cancer. For Biovica the project expand the application of DiviTum® to one of the most common forms of blood cancer where the incidence has doubled in the past decades.
Biovica CEO Anders Rylander is interviewed by the results presented at the AACR conference 1-5 April 2017. Read the interview here.
Uppsala, Sweden, April 3 2017. The latest data of the DiviTum® assay as an efficacy marker of CDK4/6 inhibition was presented in an oral session by Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, at the 2017 American Association for Cancer Research (AACR) Annual Meeting.
The latest data of the DiviTum® assay as a unique efficacy marker of CDK4/6 inhibition is available on the American Association for Cancer Research (AACR) 2017 annual meeting website. Link to the results
Anders Rylander, CEO Biovica is interviewed in Analysguiden by Aktiespararna. The interview focus on the upcoming company IPO in march 2017. The interview is only available in Swedish.
Anders Rylander, CEO will present at the Vator Securities Unicorn Summit in Stockholm on March 7, 2017. The presentation, part of the company’s planned IPO on Nasdaq First North in March 2017, is intended for investors. The purpose of the IPO is to raise funds to initiate the commercialization phase of the company’s DiviTum™ [...]